Synagis is the only FDA-approved monoclonal antibody to help protect high-risk infants against RSV.

Synagis palivizumab 100mg/1 mL Single-Dose Vial is a highly effective medication used to prevent serious respiratory infections in infants and young children caused by the respiratory syncytial virus (RSV). RSV is the most common cause of bronchiolitis and pneumonia in children under the age of one, making it a significant health concern for parents and healthcare providers. Synagis works by targeting the RSV virus and preventing it from replicating, therefore reducing the risk of severe lung infections. This medication has been shown to significantly reduce hospitalizations and even deaths in premature infants and children with lung or heart conditions. Its convenient single-dose vial form makes it easy to administer and its recommended dosage of once a month for a total of 5 doses during RSV season offers excellent protection. The benefits of Synagis palivizumab 100mg are clear, as it not only protects against potentially life-threatening infections, but also provides peace of mind for parents knowing their child is receiving the best prevention possible for RSV.

Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.

Indications:

• Synagis 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:
• with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
• with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
• with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season